When considering a PhD, choosing the right place to study is a major factor.
The Doherty Institute is home to graduate researchers from all over the world with different backgrounds, interests and motivations. We asked our current graduate researchers to tell us about their research, explain why they chose to study at the Doherty Institute and also provide some advice to prospective PhD applicants.
Dr Alex Stewart
Alex commenced a PhD with the McCarthy Group in 2022.
Research title: The role of cytochrome polymorphisms in primaquine metabolism and effects on its activity in radical cure of Plasmodium vivax infection.
Catriona Nguyen-Robertson
Catriona commenced a PhD with the Godfrey Group in 2016.
Research title: The molecular and cellular basis of antigen recognition by CD1a-restricted T cells.
Charlie Higgs
Charlie commenced a PhD with the Howden Group in 2019.
Research title: The application of whole genome sequencing to the understanding, surveillance, and control of antimicrobial resistant bacteria in Australia,
Daniel Rawlinson
Daniel commenced a PhD with the Coin Group in 2021.
Research title: The Applications and Limitations of CITE-seq for Immune Cell Profiling.
Elise Mitri
Elise commenced a PhD with the Trubiano Group in 2023.
Research title: Multi-disciplinary Health Services Approaches to Low-risk Penicillin Allergy Delabelling
Magnus Jespersen
Magnus commenced a PhD with the Davies Group ing 2019.
Research title: Characterising the molecular drivers of group A Streptococcal evolution
Dr Michael Moso
Dr Michael Moso commenced a PhD with the Lewin Group in 2023.
Research title: Nanoparticle and gene therapy approaches to HIV cure.
Navneet Kaur
Navneet commenced a PhD with the McDevitt Group in 2020.
Research title: Structural and Functional Characterisation of the WalK histidine kinase from Staphylococcus aureus.
Dr Neta Petersiel
Neta commenced a PhD with the Tong Group in 2022.
Research title: Are MRSA β-lactam susceptibility phenotypes and genotypes associated with treatment response and clinical outcomes in MRSA bloodstream infections?
Dr Ouli Xie
Dr Ouli Xie commenced a PhD with the Tong and Davies Group in 2022.
Research title: Evolution of streptococcal pathovars.
Dr Rendi Moke
Rendi commenced a PhD with the Coin Group in 2023.
Research title: Prospective study of treatment outcomes on the shorter treatment regimen among drug resistant tuberculosis with various mutations.
Dr Stephen Muhi
Stephen commenced a PhD with the Stinear Group in 2021.
Research title: Novel strategies to diagnose and control emerging infectious diseases.
